S-1: SeaStar Medical Launches Public Offering to Fuel Growth Amidst Nasdaq Compliance Scrutiny and Pivotal Trial Progress

SeaStar Medical Holding Corporation has filed an S-1 registration statement to offer up to 4.2 million shares and accompanying warrants, seeking to raise capital for its medical device development and commercialization efforts while addressing ongoing Nasdaq listing compliance issues and advancing its pivotal adult AKI clinical trial.

Summary

• SeaStar Medical is offering up to 4,237,288 shares of common stock and accompanying warrants, or pre-funded warrants and accompanying warrants, with an assumed combined public offering price of $1.18 per share.
• The company also plans to issue up to 296,610 Placement Agent Warrants.
• SeaStar Medical is a commercial-stage healthcare company focused on its Selective Cytopheretic Device (SCD) for hyperinflammation and organ failure.
• Its pediatric SCD product, QUELIMMUNE, received FDA Humanitarian Device Exemption (HDE) approval on February 21, 2024, and commenced commercial shipments in July 2024, with 5 active commercial sites as of March 31, 2025.
• The company is conducting a pivotal clinical trial (NEUTRALIZE-AKI) for its adult SCD therapy in critically ill adult patients with Acute Kidney Injury (AKI) requiring continuous renal replacement therapy (CRRT), having enrolled 108 patients as of June 12, 2025.
• The SCD therapy has received Breakthrough Device Designation (BDD) from the FDA for six therapeutic indications, including adult AKI, cardiorenal syndrome, hepatorenal syndrome, and end-stage renal disease (ESRD).
• The company reported a net loss of $3.772 million for the three months ended March 31, 2025, a significant improvement from a $12.697 million net loss for the same period in 2024.
• For the year ended December 31, 2024, the net loss was $24.830 million, compared to $26.232 million in 2023.
• Revenue for Q1 2025 was $293,000, compared to no revenue in Q1 2024, reflecting the start of commercial sales.
• Research and development expenses increased by 43% to $2.431 million in Q1 2025, driven by the expansion of the NEUTRALIZE-AKI trial from 5 to 16 sites.
• General and administrative expenses decreased by 25% to $1.684 million in Q1 2025 due to reduced accounting, legal, and consulting costs.
• The company had cash of $5.3 million as of March 31, 2025, up from $1.8 million at December 31, 2024, primarily due to financing activities.
• SeaStar Medical has an accumulated deficit of $143.3 million as of March 31, 2025, and its independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company received a Nasdaq delisting notification on June 24, 2024, for failing to maintain a minimum market value of listed securities of $35 million and has until June 22, 2025, to regain compliance.
• The company recently secured a new equity line of credit with Lincoln Park Capital Fund, LLC for up to $15.0 million over 36 months, announced on April 25, 2025.

Sentiment

Score: 4

Explanation: While the company shows progress in clinical trials and has initiated commercial sales, and has significantly reduced its net loss in the most recent quarter, the substantial doubt about its ability to continue as a going concern, recurring operating losses, negative working capital, and ongoing Nasdaq delisting risk present significant financial instability. The capital raises are crucial for survival, but also indicate a persistent need for funding and lead to dilution. The positive clinical data is promising but still requires further regulatory approval and commercial scale-up.

Positives

• FDA Humanitarian Device Exemption (HDE) approval for pediatric SCD (QUELIMMUNE) on February 21, 2024, and first commercial shipments in July 2024, establishing a new revenue stream.
• Breakthrough Device Designation (BDD) from the FDA for six therapeutic indications, which is expected to expedite clinical development and regulatory review.
• Significant reduction in net loss for Q1 2025 to $3.772 million from $12.697 million in Q1 2024, primarily due to favorable changes in fair value of financial instruments and reduced G&A expenses.
• Successful enrollment of 108 patients in the pivotal NEUTRALIZE-AKI adult clinical trial as of June 12, 2025, demonstrating progress in clinical development.
• Positive clinical outcomes from previous pediatric SCD studies (SCD-PED-01 and 02) showing a 77% survival rate and 100% dialysis independence at Day 60 for surviving patients.
• Preliminary clinical evidence suggests potential for SCD technology expansion into large patient populations for acute respiratory distress syndrome, chronic dialysis, cardiorenal syndrome, and hepatorenal syndrome.
• Successful termination of the distribution agreement with Nuwellis and transition to a direct sales model for QUELIMMUNE, allowing for more direct control over commercialization.
• New equity line of credit with Lincoln Park Capital Fund, LLC for up to $15.0 million, providing a potential source of future funding.
• Management (CEO and CMO) waived 2023 and 2024 earned bonuses to support the company's efforts to reduce liabilities.

Negatives

• The company has incurred significant losses since its inception, with an accumulated deficit of $143.3 million as of March 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern, as stated by its independent registered public accounting firm.
• The company does not have sufficient cash on hand to fund operations for at least 12 months from the issuance date of the financial statements.
• Nasdaq delisting risk due to non-compliance with the minimum market value of listed securities ($35 million) requirement, with a deadline of June 22, 2025, to regain compliance.
• The current public offering is on a 'reasonable best efforts' basis with no minimum amount of securities required to be sold, meaning the company may not raise the capital it believes is required.
• Immediate and potential future dilution for existing stockholders due to the current offering and likely future equity issuances.
• Reliance on a single supplier (Fresenius Medical Care North America) for critical SCD components, posing supply chain disruption risks.
• Ongoing legal proceedings, including a stockholder class action and a derivative action, which could divert management attention and resources and result in significant costs or damages.
• Many outstanding warrants have exercise prices significantly higher than the current common stock trading price, making their exercise unlikely in the near term and limiting potential cash proceeds from them.
• The company has a limited commercial operating history, making future revenue generation and profitability uncertain.
• The company refunded $900,000 to Nuwellis as part of the termination of the distribution agreement.

Risks

• You will experience immediate dilution in the book value per share of the Common Stock purchased in the offering.
• If you purchase our securities in this offering you may experience future dilution as a result of future equity offerings or other equity issuances.
• A substantial number of shares of Common Stock may be sold in the market following this offering, which may depress the market price for our Common Stock.
• We have broad discretion to determine how to use the funds raised in this offering, which may not enhance our operating results or the price of our Common Stock.
• The holders of Warrants and Pre-Funded Warrants purchased in this offering will have no rights as common stockholders until such warrants exercise, except as set forth in the Warrants and Pre-Funded Warrants.
• The Warrants and Pre-Funded Warrants are speculative in nature.
• This is a reasonable best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required to continue our operations.
• We have not generated revenue sufficient for positive operating cash flows, have incurred significant losses since our inception and may continue to incur significant losses for the foreseeable future.
• There is substantial doubt about our ability to continue as a going concern and if we fail to obtain additional financing, we would be forced to delay, reduce or eliminate our product development program.
• We have a limited operating history.
• We may not be able to use our net operating losses to offset future taxable income.
• We may face challenges in obtaining additional FDA approvals to market our product.
• The United States could change tariff, trade, or tax provisions related to the manufacturing and sales of our products in ways that we currently cannot predict.
• We may not be able to manage our growth effectively.
• Changing priorities within the U.S. government resulting in the loss of government grant funding could adversely impact our future growth plans.
• We will initially depend on revenue generated from a single product.
• We may fail to comply with extensive regulations of United States and foreign regulatory agencies.
• Delays in successfully completing our clinical trials could jeopardize our ability to obtain regulatory approval.
• We have limited experience with large-scale contracts with medical device manufacturers.
• We face intense competition in the medical device industry and our SCD technology may become obsolete.
• We outsource many of our operational and development activities for which we may not have full control.
• A lack of third-party coverage and reimbursement for our devices could delay or limit their adoption.
• Adverse changes in reimbursement policies and procedures by payors may impact our ability to market and sell our products.
• We are and will be exposed to product liability risks, and clinical and preclinical liability risks, which could place a substantial financial burden upon us should we be sued.
• United States legislative or FDA regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after approval is obtained.
• We are subject to stringent and changing privacy laws, regulations and standards.
• Our business operations will be adversely affected if our security measures, or those maintained on our behalf, are compromised, limited or fails.
• We depend on key personnel and our inability to attract and retain qualified personnel could impede our ability to achieve our business objectives.
• Our estimates of market opportunity, industry projections and forecasts of operating and financial results and market growth may prove to be inaccurate.
• We rely upon exclusively licensed patent rights from third parties which are subject to termination or expiration.
• If we are unable to obtain and maintain sufficient patent protection for our products, our ability to commercialize such products successfully may be adversely affected.
• If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be adversely and materially affected, and our business could be harmed.
• The United States government may exercise certain rights with regard to our inventions, or licensors inventions, developed using federal government funding.
• Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
• Our Common Stock may be delisted from Nasdaq if we do not maintain compliance with Nasdaqs continued listing requirements. If our Common Stock is delisted, it could negatively impact us.
• The trading price of our Common Stock has been volatile and is likely to be volatile in the future.
• Future sales, or the possibility of future sales, of a substantial number of shares of our Common Stock could adversely affect the price of the shares and dilute stockholders.
• We have not paid cash dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our Common Stock.
• We are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 and we intend to continue to take advantage of reduced disclosure and governance requirements applicable to emerging growth companies, which could result in our Common Stock being less attractive to investors and adversely affect the market price of our Common Stock or make it more difficult to raise capital as and when we need it.

Future Outlook

SeaStar Medical anticipates reporting topline clinical trial results for its NEUTRALIZE-AKI adult SCD pivotal trial and submitting a Pre-market Approval (PMA) application in mid-2026. The company expects to continue increasing research and development expenses to advance its SCD programs and a next-generation SCD, subject to additional funding. Future revenue generation is highly dependent on the successful rollout of QUELIMMUNE to pediatric hospitals and the eventual commercialization of the adult SCD. The company plans to explore business development opportunities and out-licensing arrangements with major medical and pharmaceutical companies to expand its solutions to chronic disease settings and scale production with manufacturing partners.

Management Comments

• "We believe our technology has the potential to overcome limitations in existing anti-inflammatory treatments and address the challenge of selectively targeting activated neutrophils and monocytes."
• "We believe that our SCD therapy is readily applicable for use in other indications, which will increase the addressable market for our SCD therapy, but will also require additional clinical studies and FDA approval."
• "We believe that our first-in-class SCD therapy can address the large potential market of over one million patients each year that face life-threatening hyperinflammatory conditions, including organ failure and potential loss of life."
• "We intend to vigorously defend the action [Class Action lawsuit]."
• "We believe this property is adequate to operate our business."
• "We believe that Mr. Schlorff is well-qualified to serve on the Board due to his intimate knowledge of our business operation, including the scientific basis, regulatory requirements and sales and marketing channels of the SCD products, as well as his extensive experience in financial planning and managing large and complex organizations."
• "We believe that Mr. Barnett is well-qualified to serve on the Board due to his extensive expertise and skills in hospital operations, risk and compliance management, which will enhance and expand the Boards oversight capabilities over our strategic directions in a complex healthcare market."
• "We believe that Ms. Baird is well-qualified to serve on the Board due to her leadership, management, and executive experience and that her service will enhance the ability of the Board to provide effective support and oversight of our operations."
• "We believe that Ms. Vincent is well-qualified to serve on the Board due to her industry expertise and experience, and that she will provide valuable insight and knowledge to our operations."
• "We believe that Mr. Van Heel is well-qualified to serve on the Board due to his extensive and deep experience in venture capital investment, financial analysis and reporting, risk management, strategic planning, and public company operations, as well as his expertise and skills in working with companies in the medical device and healthcare industries, which will provide valuable oversight and guidance to our governance."
• "We believe that Mr. Neuman is well-qualified to serve on the Board due to his extensive expertise in financial accounting, corporate governance, financial risk management, and strategic opportunities, as well as his proven track record of executing investment and business strategies for public companies, which will contribute to the Boards ability to effectively manage our growth and commercial plans."
• "The Board believes that having an independent director serving as the Chairman provides better and effective oversight and management of us as a publicly traded company, which also improves management efficiency as the Chief Executive Officer can focus on our day-to-day operations."

Industry Context

SeaStar Medical operates in the highly competitive medical device industry, specifically targeting hyperinflammation and organ failure, a field with substantial clinical demand and a lack of specific therapeutic options to neutralize over-active immune cells. The company's SCD technology aims to overcome limitations of existing anti-inflammatory treatments. The market for AKI patients on CRRT is estimated at $986 million globally ($354 million in the U.S. as of 2019), with major operators like Fresenius Medical Care Holdings, Inc. and Baxter International dominating over 80% of the U.S. market. The AKI patient population is growing at an average of 6.9% per year, and the economic burden of AKI hospitalizations is significant, estimated between $5.4 billion and $20 billion annually in the U.S. The company's health economic outcomes research suggests its pediatric SCD (QUELIMMUNE) could be cost-beneficial, potentially saving ~$70,000 per hospitalization by reducing mortality and hospital length of stay. This positions SeaStar Medical to address a critical unmet need with a potentially cost-effective solution in a growing market, despite intense competition from larger, well-resourced companies.

Comparison to Industry Standards

• The company's SCD therapy in clinical studies with over 150 pediatric and adult AKI patients on CRRT reduced mortality rates by 50%, and none of those surviving 60 days required dialysis, compared to historical mortality rates of >50% and 25% long-term dialysis dependency for standard of care.
• In the SCD-003 trial, a per-protocol analysis of patients who achieved target iCa ranges showed a 60-day mortality rate of 16% in the SCD-treated group compared to 41% in the control group, and a composite endpoint of mortality and/or dialysis dependency at day 60 was 16% vs. 58% respectively.
• Pediatric SCD studies (PED-01 and PED-02, N=22) demonstrated a survival rate of ~77% at Day 60, compared to a historical control of 50%, and 100% of surviving patients were dialysis independent by Day 60, compared to a historical control of 15% to 20% requiring dialysis.
• The company's health economic outcomes research (HEOR) estimates pediatric AKI hospitalizations involving CKRT cost over $450,000 per event, with a median length of stay (LOS) of 31 days. QUELIMMUNE therapy was projected to be cost-beneficial by lowering mortality and reducing hospital LOS by 3 days, with estimated savings of ~$70,000 per hospitalization. This suggests a favorable economic profile compared to the high existing costs.
• The company states it is not aware of any similar device that has completed regulatory approval in any country for the treatment of adults or children with acute kidney injury requiring continuous renal replacement therapy, suggesting a potentially unique market position.

Management Changes

Corporate Governance

Legal Proceedings

• Stockholder Class Action Lawsuit: Filed July 5, 2024 (amended March 4, 2025) by Forrest A K Wells, alleging material misstatements/omissions regarding business operations and FDA approval disclosures, culminating in financial statement restatement. Claims under Section 10(b) and 20(a) of the Exchange Act. Seeks compensatory damages. Company intends to vigorously defend.
• Stockholder Derivative Action Lawsuit: Filed December 13, 2024, by Jose Lazo, with factual allegations substantially similar to the Class Action. Alleges violations of Section 14(a) and 10(b) of the Exchange Act, breach of fiduciary duties, and unjust enrichment by CEO, former CFO, and certain current/former directors. Seeks damages, restitution, and injunctive relief concerning corporate governance and internal controls. Stayed as of January 30, 2025, pending resolution of motion to dismiss in Class Action.

Related Party Transactions

• Amended and Restated Registration Rights Agreement: Entered into on April 21, 2022, with certain stockholders of SeaStar Medical and LMAO, requiring registration of shares and imposing lock-up restrictions. Lock-up restrictions waived for David Humes and Michael Humes on October 25, 2022.
• Amendment to Credit Agreement with LM Funding America, Inc. (LMFA) and Amended Promissory Note: On October 28, 2022, amended Credit Agreement to extend maturity, permit prepayment, require 5.0% of future financing proceeds for repayment (after first $500k), and reduce interest rates. Secured by substantially all company assets. Fully extinguished during 2024.
• Sponsor Promissory Note: On October 28, 2022, entered into a $2.785 million note with LMFAO Sponsor, LLC (LMAO's sponsor), with similar terms to the LMFA note (extended maturity, prepayment, 5.0% repayment from future financing proceeds, 7% interest). Secured by substantially all company assets. Fully paid off on January 31, 2024.
• Unsecured Maxim Note Payable: On October 28, 2022, entered into a $4.2 million promissory note with Maxim (financial advisor) for professional fees. Matured October 30, 2023, with 7.0% interest. Required 25.0% prepayment from future financing proceeds (after first $500k). Fully paid in 2024.
• Related Party Notes (LMFA): Short-term financings with LMFA in 2023 (totaling $225k) at 7.00% interest, paid off within 30 days. No outstanding related party notes as of December 31, 2024.
• Investor D Note: On June 28, 2024, exchanged all remaining outstanding warrants held by Investor D (issued with convertible debt) into a short-term note of approximately $0.5 million at 7.0% interest. Paid in full during 2024.

Stakeholder Impact

• Shareholders: Face significant dilution from current and future equity offerings. Risk of delisting from Nasdaq could reduce liquidity and market price. Potential for substantial losses if the company fails to achieve profitability or secure sufficient funding. Legal proceedings could result in further dilution or financial penalties. No dividends expected.
• Employees: Dependence on key personnel is high. The company's ability to attract and retain qualified staff is crucial for business objectives. CEO and CMO waived bonuses to support the company, indicating a commitment but also financial strain.
• Customers (Hospitals/Clinicians): Pediatric SCD (QUELIMMUNE) is FDA approved and commercially available, offering a new therapeutic option for critically ill pediatric AKI patients. Future availability of adult SCD depends on successful clinical trials and regulatory approval. Supply chain disruptions could impact product availability.
• Suppliers: The company relies on a single supplier for critical components, posing a risk if that supplier fails to meet obligations. Efforts to find a second source are underway.
• Creditors: The company has substantial doubt about its ability to continue as a going concern, which poses a risk to creditors. Past debt obligations have been paid off or converted, but future financing needs are significant.
• Regulatory Bodies (FDA): The company is actively engaged with the FDA for approvals and designations (HDE, BDD, PMA trials), indicating compliance efforts. Post-market testing and compliance with regulations are ongoing requirements.

Next Steps

• Continue clinical development of the adult SCD for FDA approval.
• Launch and commercialize the adult SCD in the U.S. market, if regulatory approval is obtained.
• Potentially launch adult SCD in key international markets.
• Continue to invest in the commercialization of the pediatric SCD (QUELIMMUNE).
• Generate interim results from the NEUTRALIZE-AKI pivotal trial in mid-2025.
• Submit a Pre-market Approval (PMA) application for adult AKI SCD in mid-2026.
• Identify and secure various suppliers and manufacturing partners to scale production.
• Negotiate with suppliers of raw materials to establish redundancies and alternative sources.
• Explore strategic relationships with partners for raw materials, marketing, and distribution.
• Continue to develop a comprehensive reimbursement strategy with CMS, private payors, and other stakeholders.
• Address Nasdaq listing conditions to demonstrate compliance with the MVLS Requirement by June 22, 2025, including filing public disclosures and providing updated fundraising plans and income projections.
• Vigorously defend against the stockholder class action and derivative lawsuits.
• Continue to explore the application of SCD technology across a broad range of markets and indications where proinflammatory activated neutrophils and monocytes may contribute to disease progression or severity.

Key Dates

Recommendation

Keywords

Medical Device, Healthcare, Acute Kidney Injury, AKI, Sepsis, Hyperinflammation, Cytokine Storm, Selective Cytopheretic Device, SCD, QUELIMMUNE, FDA Approval, Breakthrough Device Designation, BDD, Clinical Trials, CRRT, Cardiorenal Syndrome, Hepatorenal Syndrome, ESRD, Nasdaq Listing, Capital Raise, Biotechnology, Renal Disease, Immunomodulation